Acumen Pharma enters Alzheimer's collaboration with JCR; up to $555M in milestones

Acumen Pharmaceuticals, Inc.

JCR receives upfront payment (undisclosed) plus $9.25M option fee if Acumen exercises right to develop two candidates.
Total milestones up to $555M ($40M development, $515M sales) plus single-digit royalties on sales.
Leverages Acumen's amyloid beta oligomer antibodies and JCR's transferrin-receptor BBB technology for Alzheimer's.
Company expects preclinical data package in early 2026 to support option exercise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.